| Literature DB >> 24806727 |
Johny Kongerud1, Vidar Søyseth.
Abstract
OBJECTIVES: Summarizing the knowledge status, including the morphology, possible etiological factors, and clinical expression of aluminum potroom asthma and chronic obstructive pulmonary disease related to aluminum potroom exposure.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24806727 PMCID: PMC4131937 DOI: 10.1097/JOM.0000000000000105
Source DB: PubMed Journal: J Occup Environ Med ISSN: 1076-2752 Impact factor: 2.162
Cross-Sectional Studies: Prevalence of Symptoms, Airflow Limitation, and Pulmonary Function
| Prevalence, | |||||||
|---|---|---|---|---|---|---|---|
| Symptoms | Exposure | Outcome | Index | Reference | Effect (OR) | Adjustments | |
| General population | |||||||
| Bakke et al | 629 | Al-p: ever vs never | OLD | 9 (23) | 76 (13) | 2.7 (1.2–6.1) | Age, smoking, allergy |
| Occupational population | |||||||
| Chan-Yeung et al | Potroom vs unexp | ||||||
| Potroom | |||||||
| 495 | ≥50% time (H) | Cough | 112(23) | ||||
| 302 | <50% time (M) | 52 (17) | |||||
| 713 | Unexp (U) | 100 (14) | H | ||||
| Søyseth and Kongerud | 370 | Cur TotF, mg/m3 | |||||
| ≥ 0.5 vs <0.5 | WASTH | 12 (6) | 19 (12) | 3.7 (1.4–9.6) | Age, smoking, allergy | ||
| Kongerud et al | 1760 | Duration, yr | Age, smoking, allergy | ||||
| 5–9 vs 0–4 | WASTH | 43 (9) | 50 (8) | 1.6 (1.0–2.5) | — | ||
| ≥10 vs 0–4 | WASTH | 96 (15) | 50 (8) | 3.4 (2.1–5.8) | — | ||
| Fritschi et al | Age and smoking | ||||||
| Smelter A | 924 | Potroom vs adm | Wheeze | 30 (18) | 15 (5) | 3.8 (1.9–7.6) | — |
| Smelter B | 605 | — | Wheeze | 15 (8) | 8 (4) | 1.7 (0.7–4.3) | — |
| Smelter A | 924 | — | Ch.tightn | 22 (14) | 13 (4) | 3.1 (1.5–6.5) | — |
| Smelter B | 605 | — | Ch.tightn | 10 (5) | 9 (5) | 0.9 (0.4–2.5) | — |
Adm, administration; Al-p, aluminum production; Ch.tightn, chest tightness; cur TotF, current exposure to total fluorides; FEV1, forced expiratory flow in the first second of expiration; H, high exposure; M, medium exposure; n, the number of subjects; OR, odds ratio; OLD, asthma or chronic pulmonary disease; U, unexposed; WASTH, work-related asthma-like symptoms.
Longitudinal Studies: Symptoms
| Exposure | Incidence | |||||||
|---|---|---|---|---|---|---|---|---|
| Symptoms | Entity | Scale | Outcome | IR (10−3 yr) | Effect | Adjustments | ||
| Kongerudand Samuelsen | 1301 | TotF | mg/m3 | WASTH | HR | Sex, age, smoking | ||
| — | 0.4–0.7 vs <0.4 | — | NA | NA | 3.35 (1.51–7.41) | |||
| — | >0.7 vs <0.4 | — | NA | NA | 5.20 (2.02–13.3) | |||
| Taiwoet al | 12,022 | Gas HF | mg/m3 | D asthma | NA | NA | 5.09 (2.45–10.6) | Smoking |
| Donoghue et al | NA | TotF | Year: mg/m3 | PA | ρ = 0.50 ( | None | ||
| 5,944 | — | 1996: 0.61 | — | 16 | 2.69 | |||
| 5,853 | — | 1997: 0.73 | — | 19 | 3.25 | |||
| 5,789 | — | 1998: 0.50 | — | 11 | 1.90 | |||
| 5,725 | — | 1999: 0.76 | — | 21 | 3.67 | |||
| 5,583 | — | 2000: 0.83 | — | 16 | 2.87 | |||
| 5,583 | — | 2001: 0.60 | — | 7 | 1.25 | |||
| 5,622 | — | 2002: 0.39 | — | 10 | 1.78 | |||
| 5,476 | — | 2003: 0.46 | — | 13 | 2.37 | |||
| 5,475 | — | 2004: 0.37 | — | 4 | 0.73 | |||
| 5,568 | — | 2005: 0.25 | — | 3 | 0.54 | |||
| 5,498 | — | 2006: 0.37 | — | 2 | 0.36 | |||
ρ: Spearman rho; HF, hydrogen fluoride (gas); HR, hazard ratio; N, total number of subjects; n, number of incident cases; NA, not applicable; TotF, total fluorides; WASTH, work-related asthmatic symptoms, that is, the combination of dyspnea and wheezing improving on rest days.
Cross-Sectional and Longitudinal Studies: Pulmonary Function
| Study | Exposure | Scale | OR of AFL | Effect | Adjustments | |||
|---|---|---|---|---|---|---|---|---|
| Cross-sectional | ||||||||
| Chan-Yeung et al | Potroom | FEV1 | ||||||
| 495 | Yes | ≥50% (H) | 3,913 | |||||
| 713 | Yes | <50% (M) | 3,966 | |||||
| 302 | No | Unexposed (U) | 4,003 | H−U: −90 mL; | ||||
| Bakke et al | 658 | Al-production | Ever vs never | 39 | 1.5 (0.6–4.0) | — | — | |
| Kongerud et al | 1760 | Potroom | Duration of exposure, yr | |||||
| Yes | 5–9 vs 0–4 | NA | 2.2 (1.4–3.5) | |||||
| Yes | ≥10 vs 0–4 | NA | 2.6 (1.7–3.9) | |||||
| Longitudinal | dFEV1 | |||||||
| Chan-Yeung et al | Potroom | mL/yr | Differences: mL/yr | Age, smoke, initial FEV1 | ||||
| 269 | Yes | ≥50% (H) | — | 164 | 62,6 | H−U: −0.93; | ||
| 171 | Yes | <50% (M) | — | 114 | 67.5 | M−U: −1.24; | ||
| 380 | No | Unexposed (U) | — | 308 | 62.2 | |||
| Søyseth et al | 630 | Tot part | mg/m3 | 265 | ΔFEV1: −11.9 mL/mg/m3; | Age, smoke, previous FEV1 | ||
AFL, airflow limitation; al-production, aluminum production or processing; dFEV1, annual decline in FEV1; FEV1, forced expiratory volume in the first second of expiration; ΔFEV1, mean difference of FEV1 between two consecutive measurements; N, the total number of subjects in the cohort; n, the total number of subjects in the analyzes; NA, not applicable; OR, odds ratio; Tot part, Total particulates.
Mortality Studies: Chronic Obstructive Pulmonary Disease
| Exposure | Outcome | ||||||
|---|---|---|---|---|---|---|---|
| Study | Obs Years | Entity | Scale | Deaths | Entity | Scale | SMR for the Total Cohort |
| Rønneberg | 24,996 | Potroom | Yes vs no | Total = 20* | SMR | — | 197 ( |
| Romundstad et al | 239,246 | Cum F-exp | mg/m3× yr | Total = 112 | MRR | 121 (101–146) | |
| 0 | 20 | 1 | |||||
| 0.1–7.4 vs 0 | 24 | 1.3 (0.7–2.4) | |||||
| 7.5–19.9 vs 0 | 32 | 1.9 (1.1–3.4) | |||||
| ≥20 | 36 | 2.5 (1.5–4.3) | |||||
| Gibbs et al | 214,023 | BSM | mg/m3× yr | Total = 321 | SMR | 151 (135–168) | |
| 0 | 21 | 82 (51–125) | |||||
| 0.1–1.0 | 86 | 126 (101–156) | |||||
| 2.0–3.9 | 36 | 128 (90–177) | |||||
| 4.0–7.9 | 41 | 174 (125–236) | |||||
| 8.0–15.9 | 51 | 197 (141–259) | |||||
| 16.0–31.9 | 69 | 217 (169–274) | |||||
| ≥32.0 | 17 | 175 (102–280) | |||||
| Desjardins et al | 172,799 | Cum B(a)P | μg/m3× yr | Total = 44 | SMR | 146 (106–196) | |
| 0 | 4 | 150 (41–384) | |||||
| 0.1–20.0 | 18 | 134 (80–213) | |||||
| 20.1–40.0 | 6 | 176 (57–411) | |||||
| 40.1–80.0 | 4 | 131 (36–336) | |||||
| 80.1–160.0 | 10 | 217 (104–399) | |||||
| 160.1–320.0 | 3 | 118 (24 (344) | |||||
| >320.0 | 0 | 0 (0–382) | |||||
| Friesen et al | 150,750 | Cum B(a)P | μg/m3× yr | Total = 28 | HR | 64 (42–94) | |
| T2 vs T1 | 8 | 1.58 (0.63–3.93) | |||||
| T3 vs T1 | 8 | 1.21 (0.47–3.13) | |||||
*Underlying cause of death.
BSM, benzene-soluble matter; Cum B[a]P, cumulative Benso[a]pyrene; Cum F-exp, cumulative exposure to fluorides; HR, hazard ratio; MRR, mortality rate ratio; Obs years, observation years; SMR, standardized mortality rate (per 100,000 years); T1, 0 to 9.77 μg/m3 × year; T2, 9.78 to 36.8 μg/m3 × year; T3, more than 36.8 μg/m3 × year.